2024
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus
Arends E, Zlei M, Tipton C, Cotic J, Osmani Z, de Bie F, Kamerling S, van Maurik A, Dimelow R, Gregan Y, Fox N, Rabelink T, Roth D, Sanz I, van Dongen J, van Kooten C, Teng Y. Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus. Rheumatology 2024, 63: 2387-2398. PMID: 38775637, PMCID: PMC11371378, DOI: 10.1093/rheumatology/keae286.Peer-Reviewed Original ResearchMemory B cellsSystemic lupus erythematosusCirculating memory B cellsB cellsLupus nephritisLupus erythematosusAutoreactive memory B cellsMemory B cell subsetsSLE disease activityMemory B cell phenotypeEfficacy of belimumabSerologically active patientsHigh-sensitivity flow cytometryNaive B cellsB-cell traffickingB cell activationInhibition of B cell activationRetrospective meta-analysisBelimumab initiationIntravenous belimumabSubcutaneous belimumabBelimumabDisease activityLymphocyte traffickingAutoimmune diseases
2023
Post Hoc Analyses of Biomarkers Predictive of a Renal Response to Intravenous (IV) Belimumab (BEL) Plus Standard Therapy (ST) in Patients with Lupus Nephritis (LN)
Rovin B, Furie R, Malvar A, Aranow C, Pego-Reigosa J, Zakharova E, Schwarting A, Jones-Leone A, Gilbride J, Ji B, Roth D, Curtis P, van Maurik A. Post Hoc Analyses of Biomarkers Predictive of a Renal Response to Intravenous (IV) Belimumab (BEL) Plus Standard Therapy (ST) in Patients with Lupus Nephritis (LN). Journal Of The American Society Of Nephrology 2023, 34: 972-973. DOI: 10.1681/asn.20233411s1972c.Peer-Reviewed Original Research
2021
Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) with Relapsed and Newly Diagnosed Active Lupus Nephritis (LN)
Anders H, Rovin B, Zhao M, Malvar A, Hiromura K, Jones-Leone A, González-Rivera T, Gilbride J, Madan A, Green Y, Roth D. Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) with Relapsed and Newly Diagnosed Active Lupus Nephritis (LN). Journal Of The American Society Of Nephrology 2021, 32: 48-49. DOI: 10.1681/asn.20213210s148c.Peer-Reviewed Original Research
2020
Belimumab (BEL) Improves Renal Outcomes in Active Lupus Nephritis (LN): A Phase 3 Randomized, Placebo (PBO)-Controlled Trial
Rovin B, Houssiau F, Furie R, Malvar A, Teng Y, Mok C, Contreras G, Yu X, Dolff S, Ji B, Roth D, Kleoudis C, Makowiak S, Madan A, Gilbride J, Green Y. Belimumab (BEL) Improves Renal Outcomes in Active Lupus Nephritis (LN): A Phase 3 Randomized, Placebo (PBO)-Controlled Trial. Journal Of The American Society Of Nephrology 2020, 31: 54-54. DOI: 10.1681/asn.20203110s154a.Peer-Reviewed Original Research